Compare Adaptive Biotechnologies Corp (ADPT) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $29.94. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares S&P GSCI Commodity-Indexed Trust ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | GSG | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $22.37 | $34.77 |
52-Week Low | $10.24 | $22.06 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GSG trades at $28.89, up 1.83% today, with a bullish technical signal but mixed moving averages and neutral oscillators. Recent news highlights institutional interest, with JPMorgan Chase increasing its stake by 224.3% in Q3 2025 (SEC filing, 2026-04-07). Commodity ETFs like GSG are gaining attention amid inflation fears and supply constraints, as noted by Zacks Investment Research (2026-04-07).
The outlook for GSG is supported by strong commodity market trends and institutional accumulation, but risks include volatility from geopolitical events and inflation shifts. Key support sits at $28, with resistance near $29. Wall Street sentiment is cautiously optimistic due to macroeconomic tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
